BridgeBio Pharma Inc (NASDAQ:BBIO)
| 26.76 Delayed Data As of Apr 08 |  +2.51 / +10.28%Today’s Change | 14.23 Today|||52-Week Range 48.36 | -23.65% Year-to-Date |
Latest BBIO News | Press Releases
No recent news for BridgeBio Pharma Inc.
Today’s Trading
| Previous close | 24.42 |
| Today’s open | 25.09 |
| Day’s range | 23.19 - 27.20 |
| Volume | 1,247,344 |
| Average volume (3 months) | 778,451 |
| Market cap | $3.1B |
Data as of 4:00pm ET, 04/08/2020
Growth & Valuation
| Earnings growth (last year) | -111.73% |
| Earnings growth (this year) | -10.43% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 90.82 |
| Price/Book | 7.50 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AKRXAkorn Inc | +0.00 | +1.37% |
| TEVATeva Pharmaceutical | +0.01 | +0.10% |
| BGNEBeigene Ltd | +4.36 | +3.20% |
Data as of 7:44pm ET, 04/08/2020
Financials
| Next reporting date | June 3, 2020 |
| EPS forecast (this quarter) | -$0.69 |
| Annual revenue (last year) | $40.6M |
| Annual profit (last year) | -$260.6M |
| Net profit margin | -642.47% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Generic |
No executives to display |
Corporate headquarters Palo Alto, California |
Forecasts
